Genentech DRC A PHASE III, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC RETINOPATHY (PAVILION)
Research Grant
Administered By
Ophthalmology
Awarded By
Genentech, Inc.
Start Date
January 1, 2020
End Date
March 31, 2024
Administered By
Ophthalmology
Awarded By
Genentech, Inc.
Start Date
January 1, 2020
End Date
March 31, 2024